From the present results, the PD-1/PD-L1 axis may function in immune tolerance to treatment with HDAC inhibitors especially with ambient IFN-γ, whereas HDAC inhibitors directly impair MM cell viability. Here, HDAC9 is linked to Miyoshi myopathy.